利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

60 条记录 (耗时 0.021 秒)

    MULTI-DAY PATCH FOR THE TRANSDERMAL ADMINISTRATION OF ROTIGOTINE
    2.
    发明公开
    MULTI-DAY PATCH FOR THE TRANSDERMAL ADMINISTRATION OF ROTIGOTINE 有权
    几天补丁罗替高汀透皮给药

    公开(公告)号：EP2922533A1

    公开(公告)日：2015-09-30

    申请号：EP13795432.7

    申请日：2013-11-21

    申请人： UCB Pharma GmbH ,  LTS LOHMANN Therapie-Systeme AG

    发明人： CAWELLO, Willi ,  LAPPERT, Aurelia ,  KASSNER, Kristina ,  WOLFF, Hans-Michael ,  MÜLLER, Walter ,  LEONHARD, Johannes Josef ,  EMGENBROICH, Marco

    IPC分类号： A61K9/70 ,  A61K31/381

    CPC分类号： A61K9/7092 ,  A61K9/7069 ,  A61K9/7084 ,  A61K31/381 ,  B32B37/12 ,  B32B2556/00

    摘要： The present invention relates to a transdermal therapeutic system, comprising (a) a backing layer, (b) a solvent -based self-adhesive matrix layer containing rotigotine as active ingredient, and (c) a release liner, wherein the self- adhesive matrix layer has a coating weight of about 75-400 g/m
    2 and comprises a reservoir layer containing about 9-25 wt.-% rotigotine based on the weight of the reservoir layer, a kit comprising two transdermal therapeutic systems of the present invention as well as a method for the preparation of the transdermal therapeutic system of the present invention. In addition, the present invention relates to a transdermal therapeutic system comprising rotigotine as active ingredient for use in the treatment of patients suffering from Parkinson's disease, Parkinson's plus syndrome, depression, fibromyalgia and the restless-legs syndrome and for use in the treatment or prevention of dopaminergic neuron loss or cognitive disorders by transdermal administration of rotigotine once or twice weekly, wherein the transdermal therapeutic system comprises a backing layer, a solvent -based rotigotine containing self-adhesive matrix layer as well as a release liner and is adapted to allow for the transdermal administration of therapeutically effective amounts of rotigotine for at least 3 days.

    THERAPEUTIC PATCH WITH POLYSILOXANE MATRIX COMPRISING CAPSAICIN
    7.
    发明公开
    THERAPEUTIC PATCH WITH POLYSILOXANE MATRIX COMPRISING CAPSAICIN 有权
    辣椒素的含聚硅氧烷MATRIX疗效PATCH

    公开(公告)号：EP1613297A1

    公开(公告)日：2006-01-11

    申请号：EP03779987.1

    申请日：2003-11-19

    申请人： LTS LOHMANN Therapie-Systeme AG

    发明人： MÜLLER, Walter

    IPC分类号： A61K31/165 ,  A61K9/70 ,  A61P25/02

    CPC分类号： A61K31/165 ,  A61K9/703 ,  A61K9/7069 ,  Y10T156/10

    摘要： Topical patch containing capsaicin or a capsaicin analog, process for its preparation and its use. The invention relates to a topical patch comprising a therapeutic compound-impermeable backing layer, a self-adhesive matrix based on polysiloxanes and containing capsaicin or a therapeutic compound analogous to capsaicin, and a protective film to be removed before use, in which the matrix contains liquid microreservoirs based on an amphiphilic solvent, in which the therapeutic compound is present in completely dissolved form and the concentration of the therapeutic compound in the microreservoir droplets is below the saturation concentration. The invention furthermore relates to a process for its production and its use in the treatment of neuropathic pain.

    TRANSDERMALES THERAPEUTISCHES SYSTEM MIT FENTANYL BZW. VERWANDTEN SUBSTANZEN
    10.
    发明公开
    TRANSDERMALES THERAPEUTISCHES SYSTEM MIT FENTANYL BZW. VERWANDTEN SUBSTANZEN 无效
    透皮治疗系统芬太尼

    公开(公告)号：EP1418894A2

    公开(公告)日：2004-05-19

    申请号：EP02762336.2

    申请日：2002-07-10

    申请人： LTS Lohmann Therapie-Systeme AG

    发明人： MÜLLER, Walter ,  HILLE, Thomas

    IPC分类号： A61K9/70 ,  A61K31/4468

    CPC分类号： A61K9/7061 ,  A61K31/4468

    摘要： The invention relates to a transdermal therapeutic system (TTS), comprising a backing layer, which is permeable to the active ingredient, at least one matrix layer, comprising fentanyl or an active agent analogous to fentanyl, based on polyacrylate and a protective layer to be removed before usage, characterised in that the polyacrylate polymer is self-adhesive, free of carboxyl groups, has a saturation solubility for fentanyl of 3 to 20 wt. %, preferably of 4 to 12 and particularly of 5 to 10 wt. % and the layers contain at least 80 % of the included active ingredient in a molecularly-dispersed, dissolved form.